Richard Howard Drew
Professor in Medicine
Pharmacokinetics/pharmacodynamics of antimicrobials, antifungal use in compromised hosts, antimicrobial stewardship, prediction and therapy of multidrug-resistant pathogens, aerosolized antimicrobials
Current Appointments & Affiliations
- Professor in Medicine, Medicine, Infectious Diseases, Medicine 2021
Contact Information
- 169 Hanes House, Trent Drive, Durham, NC 27710
- Duke Box 102359, Durham, NC 27710
-
richard.drew@duke.edu
(919) 681-6793
- Background
-
Education, Training, & Certifications
- Pharm.D., University of North Carolina - Chapel Hill 1999
- M.S., University of North Carolina - Chapel Hill 1989
- Resident, Hospital Pharmacy, Duke University School of Medicine 1980 - 1981
-
Previous Appointments & Affiliations
- Professor in Medicine, Medicine, Infectious Diseases, Medicine 2019 - 2020
- Associate Professor in Medicine, Medicine, Infectious Diseases, Medicine 2007 - 2019
- Assistant Professor in Medicine, Medicine, Infectious Diseases, Medicine 2006 - 2007
- Assistant Research Professor in Medicine, Medicine, Infectious Diseases, Medicine 2002 - 2006
- Instructor, Medicine, Infectious Diseases, Medicine 1987 - 2002
- Research
-
External Relationships
- UpToDate, Inc. (Wolters Kluwer Health)
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Perez, Reinaldo, Michael E. Yarrington, Martha B. Adams, Connor R. Deri, Richard H. Drew, Michael J. Smith, Justin Spivey, Rebekah H. Wrenn, and Rebekah W. Moehring. “Pandemic hits: Evaluation of an antimicrobial stewardship program website for hospital communication during the coronavirus disease 2019 (COVID-19) pandemic.” Infect Control Hosp Epidemiol, April 12, 2023, 1–3. https://doi.org/10.1017/ice.2023.43.Full Text Link to Item
-
Moehring, Rebekah W., Angelina Davis, Elizabeth Dodds Ashley, April P. Dyer, Richard H. Drew, Yuliya Loknyghina, Melissa D. Johnson, et al. “Harvesting the low-hanging fruit? Comparative assessment of intravenous to oral route antimicrobial conversion policy implementation.” Infect Control Hosp Epidemiol, July 15, 2022, 1–5. https://doi.org/10.1017/ice.2022.158.Full Text Link to Item
-
Drew, Richard H., and John R. Perfect. “Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.” J Fungi (Basel) 8, no. 2 (February 21, 2022). https://doi.org/10.3390/jof8020212.Full Text Link to Item
-
Muro, Florida J., Furaha S. Lyamuya, Charles Kwobah, John Bollinger, Champica K. Bodinayake, Ajith Nagahawatte, Bhagya Piyasiri, et al. “Opportunities for Improving Antimicrobial Stewardship: Findings From a Prospective, Multi-Center Study in Three Low- or Middle-Income Countries.” Front Public Health 10 (2022): 848802. https://doi.org/10.3389/fpubh.2022.848802.Full Text Link to Item
-
Rolfe, Robert, Charles Kwobah, Florida Muro, Anushka Ruwanpathirana, Furaha Lyamuya, Champica Bodinayake, Ajith Nagahawatte, et al. “Barriers to implementing antimicrobial stewardship programs in three low- and middle-income country tertiary care settings: findings from a multi-site qualitative study.” Antimicrob Resist Infect Control 10, no. 1 (March 25, 2021): 60. https://doi.org/10.1186/s13756-021-00929-4.Full Text Link to Item
-
Heil, Emily L., Samuel L. Aitken, David E. Nix, Richard Drew, Warren E. Rose, Susan L. Davis, Julie Ann Justo, Douglas N. Fish, Jason M. Pogue, and Jason M. Society of Infectious Diseases Pharmacists. “Recommended Revisions to the National SEP-1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper.” Pharmacotherapy 40, no. 4 (April 2020): 368–71. https://doi.org/10.1002/phar.2384.Full Text Link to Item
-
Livengood, S. J., R. H. Drew, and J. R. Perfect. “Combination Therapy for Invasive Fungal Infections.” Current Fungal Infection Reports 14, no. 1 (March 1, 2020): 40–49. https://doi.org/10.1007/s12281-020-00369-4.Full Text
-
Sheng, Tianchen, Gaya B. Wijayaratne, Thushani M. Dabrera, Richard J. Drew, Ajith Nagahawatte, Champica K. Bodinayake, Ruvini Kurukulasooriya, et al. “Point-prevalence study of antimicrobial use in public hospitals in southern Sri Lanka identifies opportunities for improving prescribing practices.” Infect Control Hosp Epidemiol 40, no. 2 (February 2019): 224–27. https://doi.org/10.1017/ice.2018.321.Full Text Link to Item
-
Hill, Brandon, Richard H. Drew, and Dustin Wilson. “Impact of select risk factors on treatment outcome in adults with candidemia.” Pharm Pract (Granada) 17, no. 3 (2019): 1561. https://doi.org/10.18549/PharmPract.2019.3.1561.Full Text Link to Item
-
Le Maréchal, Marion, Gianpiero Tebano, Annelie A. Monnier, Niels Adriaenssens, Inge C. Gyssens, Benedikt Huttner, Romina Milanic, et al. “Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure.” J Antimicrob Chemother 73, no. suppl_6 (June 1, 2018): vi40–49. https://doi.org/10.1093/jac/dky117.Full Text Link to Item
-
Monnier, Annelie A., Jeroen Schouten, Marion Le Maréchal, Gianpiero Tebano, Céline Pulcini, Mirjana Stanic Benic, Vera Vlahovic-Palcevski, et al. “Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure.” J Antimicrob Chemother 73, no. suppl_6 (June 1, 2018): vi30–39. https://doi.org/10.1093/jac/dky116.Full Text Link to Item
-
Stanic Benic, Mirjana, Romina Milanic, Annelie A. Monnier, Inge C. Gyssens, Niels Adriaenssens, Ann Versporten, Veronica Zanichelli, et al. “Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure.” J Antimicrob Chemother 73, no. suppl_6 (June 1, 2018): vi50–58. https://doi.org/10.1093/jac/dky118.Full Text Link to Item
-
Versporten, Ann, Inge C. Gyssens, Céline Pulcini, Annelie A. Monnier, Jeroen Schouten, Romina Milanic, Mirjana Stanic Benic, et al. “Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure.” J Antimicrob Chemother 73, no. suppl_6 (June 1, 2018): vi59–66. https://doi.org/10.1093/jac/dky119.Full Text Link to Item
-
Turner, Nicholas A., Rebekah Moehring, Christina Sarubbi, Rebekah H. Wrenn, Richard H. Drew, Coleen K. Cunningham, Vance G. Fowler, and Deverick J. Anderson. “Influence of Reported Penicillin Allergy on Mortality in MSSA Bacteremia.” Open Forum Infect Dis 5, no. 3 (March 2018): ofy042. https://doi.org/10.1093/ofid/ofy042.Full Text Open Access Copy Link to Item
-
Bowers, Riley D., April A. Cooper, Catherine L. Wente, Dustin T. Wilson, Steven W. Johnson, and Richard H. Drew. “Evaluation of a vancomycin dosing nomogram in obese patients weighing at least 100 kilograms.” Pharm Pract (Granada) 16, no. 3 (2018): 1204. https://doi.org/10.18549/PharmPract.2018.03.1204.Full Text Link to Item
-
Jones, Travis M., Richard H. Drew, Dustin T. Wilson, Christina Sarubbi, and Deverick J. Anderson. “Impact of automatic infectious diseases consultation on the management of fungemia at a large academic medical center.” Am J Health Syst Pharm 74, no. 23 (December 1, 2017): 1997–2003. https://doi.org/10.2146/ajhp170113.Full Text Link to Item
-
Bowers, Riley, Robert Tunney, Kim Kelly, Beth Mills, Katie Trotta, C Neil Wheeless, and Richard Drew. “Impact of Standardized Simulated Patients on First-Year Pharmacy Students' Knowledge Retention of Insulin Injection Technique and Counseling Skills.” Am J Pharm Educ 81, no. 6 (August 2017): 113. https://doi.org/10.5688/ajpe816113.Full Text Link to Item
-
Schuts, Emelie C., Caroline M. van den Bosch, Inge C. Gyssens, Bart-Jan Kullberg, Maurine A. Leverstein-van Hall, Stephanie Natsch, Fre Sebens, Martha B. Adams, Richard Drew, and Jan M. Prins. “Adoption of a national antimicrobial guide (SWAB-ID) in the Netherlands.” Eur J Clin Pharmacol 72, no. 2 (February 2016): 249–52. https://doi.org/10.1007/s00228-015-1969-x.Full Text Link to Item
-
Wilson, Dustin T., V Paul Dimondi, Steven W. Johnson, Travis M. Jones, and Richard H. Drew. “Role of isavuconazole in the treatment of invasive fungal infections.” Ther Clin Risk Manag 12 (2016): 1197–1206. https://doi.org/10.2147/TCRM.S90335.Full Text Open Access Copy Link to Item
-
Garner, Bronwen, Yuliya Lokhnygina, Elizabeth Dodds-Ashley, Melissa Johnson, Richard H. Drew, Angelina Davis, Daniel J. Sexton, Deverick Anderson, and Rebekah W. Moehring. “Harvesting the Low Hanging Fruit: A Benchmarking Tool for Implementation of Intravenous to Oral Antibiotic Switch Programs in 14 Southeastern Community Hospitals.” Open Forum Infect Dis 2, no. Suppl 1 (December 2015): 150. https://doi.org/10.1093/ofid/ofv133.28.Full Text Open Access Copy Link to Item
-
Moehring, Rebekah W., Kevin C. Hazen, Myra R. Hawkins, Richard H. Drew, Daniel J. Sexton, and Deverick J. Anderson. “Challenges in Preparation of Cumulative Antibiogram Reports for Community Hospitals.” J Clin Microbiol 53, no. 9 (September 2015): 2977–82. https://doi.org/10.1128/JCM.01077-15.Full Text Link to Item
-
Payk, Stephanie L., Richard H. Drew, Jennifer D. Smith, Michael R. Jiroutek, and Melissa A. Holland. “Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.” Clin Ther 37, no. 7 (July 1, 2015): 1477-1482.e1. https://doi.org/10.1016/j.clinthera.2015.04.011.Full Text Link to Item
-
Allen, David, Dustin Wilson, Richard Drew, and John Perfect. “Azole antifungals: 35 years of invasive fungal infection management.” Expert Rev Anti Infect Ther 13, no. 6 (June 2015): 787–98. https://doi.org/10.1586/14787210.2015.1032939.Full Text Link to Item
-
DiMondi, V Paul, Mary L. Townsend, and Richard H. Drew. “Risk factors associated with unfavorable short-term treatment outcome in patients with documented Pseudomonas aeruginosa infection.” Int J Clin Pharm 37, no. 2 (April 2015): 348–54. https://doi.org/10.1007/s11096-015-0067-6.Full Text Link to Item
-
Burgess, Lindsey D., and Richard H. Drew. “Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.” Pharmacotherapy 34, no. 7 (July 2014): 670–76. https://doi.org/10.1002/phar.1442.Full Text Link to Item
-
Kung, Hsiang-Chi, Melissa D. Johnson, Richard H. Drew, Paramita Saha-Chaudhuri, and John R. Perfect. “Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.” Cancer Med 3, no. 3 (June 2014): 667–73. https://doi.org/10.1002/cam4.225.Full Text Open Access Copy Link to Item
-
Spivey, J. R., R. H. Drew, and J. R. Perfect. “Future strategies for the treatment of cryptococcal meningoencephalitis in pediatric patients.” Expert Opinion on Orphan Drugs 2, no. 3 (January 1, 2014): 245–57. https://doi.org/10.1517/21678707.2014.880649.Full Text
-
Drew, Richard H., Mary L. Townsend, Melanie W. Pound, Steven W. Johnson, and John R. Perfect. “Recent advances in the treatment of life-threatening, invasive fungal infections.” Expert Opin Pharmacother 14, no. 17 (December 2013): 2361–74. https://doi.org/10.1517/14656566.2013.838217.Full Text Link to Item
-
Dimondi, V. P., and R. H. Drew. “Aerosolized antifungals for the prevention and treatment of invasive fungal infections.” Current Fungal Infection Reports 7, no. 2 (June 1, 2013): 110–18. https://doi.org/10.1007/s12281-013-0137-y.Full Text
-
Johnson, Steven W., Deverick J. Anderson, D Byron May, and Richard H. Drew. “Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admission.” Infect Control Hosp Epidemiol 34, no. 4 (April 2013): 385–92. https://doi.org/10.1086/669858.Full Text Link to Item
-
Johnson, S. W., R. H. Drew, and D. B. May. “How long to treat with antibiotics following amputation in patients with diabetic foot infections? Are the 2012 IDSA DFI guidelines reasonable?” J Clin Pharm Ther 38, no. 2 (April 2013): 85–88. https://doi.org/10.1111/jcpt.12034.Full Text Link to Item
-
Dodds Ashley, Elizabeth, Richard Drew, Melissa Johnson, Robert Danna, Dominika Dabrowski, Valery Walker, Manishi Prasad, Barbara Alexander, George Papadopoulos, and John Perfect. “Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options.” Pharmacotherapy 32, no. 10 (October 2012): 890–901. https://doi.org/10.1002/j.1875-9114.2012.01124.Full Text Link to Item
-
Panosh, Nicole, Richardd Rew, and Michelle Sharpe. “Effect of closed-loop order processing on the time to initial antimicrobial therapy.” Am J Health Syst Pharm 69, no. 16 (August 15, 2012): 1423–26. https://doi.org/10.2146/ajhp100644.Full Text Link to Item
-
Anderson, Deverick J., Becky Miller, Ruchit Marfatia, and Richard Drew. “Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation.” Infect Control Hosp Epidemiol 33, no. 6 (June 2012): 589–93. https://doi.org/10.1086/665721.Full Text Link to Item
-
Davis, Megan E., Deverick J. Anderson, Michelle Sharpe, Luke F. Chen, and Richard H. Drew. “Constructing unit-specific empiric treatment guidelines for catheter-related and primary bacteremia by determining the likelihood of inadequate therapy.” Infect Control Hosp Epidemiol 33, no. 4 (April 2012): 416–20. https://doi.org/10.1086/664756.Full Text Link to Item
-
Pitman, Stuart K., Richard H. Drew, and John R. Perfect. “Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.” Expert Opin Emerg Drugs 16, no. 3 (September 2011): 559–86. https://doi.org/10.1517/14728214.2011.607811.Full Text Link to Item
-
DiMondi, V Paul, Richard H. Drew, and Luke F. Chen. “Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.” Expert Rev Anti Infect Ther 9, no. 8 (August 2011): 567–72. https://doi.org/10.1586/eri.11.82.Full Text Link to Item
-
Pound, Melanie W., Mary L. Townsend, Vincent Dimondi, Dustin Wilson, and Richard H. Drew. “Overview of treatment options for invasive fungal infections.” Med Mycol 49, no. 6 (August 2011): 561–80. https://doi.org/10.3109/13693786.2011.560197.Full Text Link to Item
-
Holt, Shannon L., and Richard H. Drew. “Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.” Am J Health Syst Pharm 68, no. 13 (July 1, 2011): 1207–20. https://doi.org/10.2146/ajhp100456.Full Text Link to Item
-
Bosso, J. A., and R. H. Drew. “Application of antimicrobial stewardship to optimise management of community acquired pneumonia.” Int J Clin Pract 65, no. 7 (July 2011): 775–83. https://doi.org/10.1111/j.1742-1241.2011.02704.x.Full Text Link to Item
-
Townsend, Mary L., Melanie W. Pound, and Richard H. Drew. “Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.” Infect Drug Resist 4 (2011): 77–86. https://doi.org/10.2147/IDR.S6030.Full Text Link to Item
-
Drew, R. H., and M. L. Townsend. “Antifungal drug resistance: Clinical relevance and impact of antifungal drug use.” Current Fungal Infection Reports 4, no. 2 (June 1, 2010): 129–36. https://doi.org/10.1007/s12281-010-0013-y.Full Text
-
Pound, Melanie W., Mary L. Townsend, and Richard H. Drew. “Echinocandin pharmacodynamics: review and clinical implications.” J Antimicrob Chemother 65, no. 6 (June 2010): 1108–18. https://doi.org/10.1093/jac/dkq081.Full Text Link to Item
-
Wilson, Dustin T., Richard H. Drew, and John R. Perfect. “Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.” Mycopathologia 168, no. 6 (December 2009): 313–27. https://doi.org/10.1007/s11046-009-9193-9.Full Text Link to Item
-
Drew, Richard H., Roger White, Conan MacDougall, Elizabeth D. Hermsen, Robert C. Owens, and Robert C. Society of Infectious Diseases Pharmacists. “Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.” Pharmacotherapy 29, no. 5 (May 2009): 593–607. https://doi.org/10.1592/phco.29.5.593.Full Text Link to Item
-
Ernst, Erika J., Michael E. Klepser, John A. Bosso, Michael J. Rybak, Elizabeth D. Hermsen, Marisel Segarra-Newnham, and Richard H. Drew. “Recommendations for training and certification for pharmacists practicing, mentoring, and educating in infectious diseases pharmacotherapy.” Pharmacotherapy 29, no. 4 (April 2009): 482–88. https://doi.org/10.1592/phco.29.4.482.Full Text Link to Item
-
Drew, Richard H. “Antimicrobial stewardship programs: how to start and steer a successful program.” J Manag Care Pharm 15, no. 2 Suppl (March 2009): S18–23. https://doi.org/10.18553/jmcp.2009.15.s2.18.Full Text Link to Item
-
Drew, Richard H. “Antimicrobial Stewardship Programs: How to Start and Steer a Successful Program.” Journal of Managed Care Pharmacy 15, no. 2 (March 1, 2009): S18–23.Link to Item
-
Smith, Winter J., Richard H. Drew, and John R. Perfect. “Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.” Expert Rev Anti Infect Ther 7, no. 2 (March 2009): 165–81. https://doi.org/10.1586/14787210.7.2.165.Full Text Link to Item
-
Smith, Winter J., and Richard H. Drew. “Telavancin: a new lipoglycopeptide for gram-positive infections.” Drugs Today (Barc) 45, no. 3 (March 2009): 159–73. https://doi.org/10.1358/dot.2009.45.3.1343792.Full Text Link to Item
-
Drew, Richard H. “Aerosol and other novel administrations for prevention and treatment of invasive aspergillosis.” Med Mycol 47 Suppl 1 (2009): S355–61. https://doi.org/10.1080/13693780802247710.Full Text Link to Item
-
Tamura, Kimberly, and Richard Drew. “Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.” Drugs Today (Barc) 44, no. 7 (July 2008): 515–30. https://doi.org/10.1358/dot.2008.44.7.1230943.Full Text Link to Item
-
Goodwin, Megan L., and Richard H. Drew. “Antifungal serum concentration monitoring: an update.” J Antimicrob Chemother 61, no. 1 (January 2008): 17–25. https://doi.org/10.1093/jac/dkm389.Full Text Link to Item
-
Lalani, Tahaniyat, Jay B. Varkey, Richard Drew, Lizzie Harrell, Sarah McGarry, John G. Engemann, Melissa D. Johnson, and Keith S. Kaye. “Analysis of two- and three-year trends in antimicrobial resistance in intensive care units using unit-specific antibiograms.” Scand J Infect Dis 40, no. 8 (2008): 672–74. https://doi.org/10.1080/00365540801971403.Full Text Link to Item
-
Townsend, Mary L., Melanie W. Pound, and Richard H. Drew. “Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.” Ther Clin Risk Manag 3, no. 6 (December 2007): 1059–70.Link to Item
-
Drew, Richard H. “Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?” Ann Pharmacother 41, no. 4 (April 2007): 690–92. https://doi.org/10.1345/aph.1K051.Full Text Link to Item
-
Drew, Richard H. “Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.” Pharmacotherapy 27, no. 2 (February 2007): 227–49. https://doi.org/10.1592/phco.27.2.227.Full Text Link to Item
-
Townsend, M. L., M. W. Pound, and R. H. Drew. “Tigecycline: a new glycylcycline antimicrobial.” Int J Clin Pract 60, no. 12 (December 2006): 1662–72. https://doi.org/10.1111/j.1742-1241.2006.01188.x.Full Text Link to Item
-
Drew, Richard. “Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.” Int J Antimicrob Agents 27 Suppl 1 (June 2006): 36–44. https://doi.org/10.1016/j.ijantimicag.2006.03.018.Full Text Link to Item
-
Drew, Richard H., Kensaku Kawamoto, and Martha B. Adams. “Information technology for optimizing the management of infectious diseases.” Am J Health Syst Pharm 63, no. 10 (May 15, 2006): 957–65. https://doi.org/10.2146/ajhp050315.Full Text Link to Item
-
Turner, Michelle S., Richard H. Drew, and John R. Perfect. “Emerging echinocandins for treatment of invasive fungal infections.” Expert Opin Emerg Drugs 11, no. 2 (May 2006): 231–50. https://doi.org/10.1517/14728214.11.2.231.Full Text Link to Item
-
Wise, Gilbert J. “Do not abandon amphotericin B as an antifungal bladder irrigant.” Clin Infect Dis 41, no. 7 (October 1, 2005): 1073–74. https://doi.org/10.1086/444384.Full Text Link to Item
-
Drew, R. H., R. R. Arthur, and J. R. Perfect. “Reply to Wise.” Clinical Infectious Diseases 41, no. 7 (October 1, 2005): 1074–1074. https://doi.org/10.1086/444385.Full Text
-
Drew, Richard H., Rebekah R. Arthur, and John R. Perfect. “Is it time to abandon the use of amphotericin B bladder irrigation?” Clin Infect Dis 40, no. 10 (May 15, 2005): 1465–70. https://doi.org/10.1086/429722.Full Text Link to Item
-
Gibbs, Winter J., Richard H. Drew, and John R. Perfect. “Liposomal amphotericin B: clinical experience and perspectives.” Expert Rev Anti Infect Ther 3, no. 2 (April 2005): 167–81. https://doi.org/10.1586/14787210.3.2.167.Full Text Link to Item
-
Gibbs, W. J., R. H. Drew, and J. R. Perfect. “Liposomal amphotericin B: Clinical experience and perspectives.” Expert Review of Anti Infective Therapy 3, no. 2 (2005): 167–81. https://doi.org/10.1586/14737140.3.2.167.Full Text
-
Drew, Richard H., and Richard H. American College of Clinical Pharmacy. “Key references in infectious diseases pharmacotherapy.” Pharmacotherapy 24, no. 11 (November 2004): 1586–93. https://doi.org/10.1592/phco.24.16.1586.50954.Full Text Link to Item
-
Perfect, John R., Elizabeth Dodds Ashley, and Richard Drew. “Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.” Clin Infect Dis 39 Suppl 4 (October 15, 2004): S207–10. https://doi.org/10.1086/421958.Full Text Link to Item
-
Arthur, Rebekah R., Richard H. Drew, and John R. Perfect. “Novel modes of antifungal drug administration.” Expert Opin Investig Drugs 13, no. 8 (August 2004): 903–32. https://doi.org/10.1517/13543784.13.8.903.Full Text Link to Item
-
Drew, Richard H., Elizabeth Dodds Ashley, Daniel K. Benjamin, R. Duane Davis, Scott M. Palmer, and John R. Perfect. “Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.” Transplantation 77, no. 2 (January 27, 2004): 232–37. https://doi.org/10.1097/01.TP.0000101516.08327.A9.Full Text Link to Item
-
Johnson, Melissa D., Carol D. Hamilton, Richard H. Drew, Linda L. Sanders, Gennethel J. Pennick, and John R. Perfect. “A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution.” J Antimicrob Chemother 51, no. 2 (February 2003): 453–57. https://doi.org/10.1093/jac/dkg089.Full Text Link to Item
-
Gallagher, Jason C., Elizabeth S. Dodds Ashley, Richard H. Drew, and John R. Perfect. “Antifungal pharmacotherapy for invasive mould infections.” Expert Opin Pharmacother 4, no. 2 (February 2003): 147–64. https://doi.org/10.1517/14656566.4.2.147.Full Text Link to Item
-
Loeffler, Ann M., Richard H. Drew, John R. Perfect, Nadine I. Grethe, J. W. Stephens, Sharon L. Gray, and George H. Talbot. “Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients.” Pediatr Infect Dis J 21, no. 10 (October 2002): 950–56. https://doi.org/10.1097/00006454-200210000-00013.Full Text Link to Item
-
Pound, Melanie W., Richard H. Drew, and John R. Perfect. “Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia.” Curr Opin Infect Dis 15, no. 2 (April 2002): 183–94. https://doi.org/10.1097/00001432-200204000-00014.Full Text Link to Item
-
Palmer, S. M., R. H. Drew, J. D. Whitehouse, V. F. Tapson, R. D. Davis, R. R. McConnell, S. S. Kanj, and J. R. Perfect. “Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.” Transplantation 72, no. 3 (August 15, 2001): 545–48. https://doi.org/10.1097/00007890-200108150-00036.Full Text Link to Item
-
St Clair, E. W., W. E. Wilkinson, D. S. Pisetsky, D. J. Sexton, R. Drew, V. B. Kraus, and R. A. Greenwald. “The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.” Arthritis Rheum 44, no. 5 (May 2001): 1043–47. https://doi.org/10.1002/1529-0131(200105)44:5<1043::AID-ANR183>3.0.CO;2-C.Full Text Link to Item
-
Dodds, E. S., R. H. Drew, D. Byron May, J. A. Gouveia-Pisano, J. B. Washam, K. B. Fulton, and B. Luna. “Impact of a pharmacy student-based inpatient pneumococcal vaccination program.” American Journal of Pharmaceutical Education 65, no. 3 (January 1, 2001): 258–60.
-
Dodds, E. S., R. H. Drew, and J. R. Perfect. “Antifungal pharmacodynamics: review of the literature and clinical applications.” Pharmacotherapy 20, no. 11 (November 2000): 1335–55. https://doi.org/10.1592/phco.20.17.1335.34901.Full Text Link to Item
-
Drew, R. H., J. R. Perfect, L. Srinath, E. Kurkimilis, M. Dowzicky, and G. H. Talbot. “Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.” J Antimicrob Chemother 46, no. 5 (November 2000): 775–84. https://doi.org/10.1093/jac/46.5.775.Full Text Link to Item
-
Luna, B., R. H. Drew, and J. R. Perfect. “Agents for treatment of invasive fungal infections.” Otolaryngol Clin North Am 33, no. 2 (April 2000): 277–99. https://doi.org/10.1016/s0030-6665(00)80005-5.Full Text Link to Item
-
Hamilton, C. D., R. Drew, S. W. Janning, J. K. Latour, and S. Hayward. “Excessive use of vancomycin: a successful intervention strategy at an academic medical center.” Infect Control Hosp Epidemiol 21, no. 1 (January 2000): 42–45. https://doi.org/10.1086/501703.Full Text Link to Item
-
Dodds, E. S., D. B. May, and R. H. Drew. “Recent changes in vaccination guidelines. An update on vaccines and target population initiatives.” N C Med J 61, no. 6 (2000): 326–32.Link to Item
-
Sexton, D. J., M. J. Tenenbaum, W. R. Wilson, J. M. Steckelberg, A. D. Tice, D. Gilbert, W. Dismukes, R. H. Drew, and D. T. Durack. “Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group.” Clin Infect Dis 27, no. 6 (December 1998): 1470–74. https://doi.org/10.1086/515038.Full Text Link to Item
-
Drew, R. H. “Programs promoting timely sequential antimicrobial therapy: an American perspective.” J Infect 37 Suppl 1 (July 1998): 3–9. https://doi.org/10.1016/s0163-4453(98)92677-9.Full Text Link to Item
-
Johnson, M. D., R. H. Drew, and J. R. Perfect. “Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.” Pharmacotherapy 18, no. 5 (1998): 1053–61.Link to Item
-
Anderson, N., R. Drew, S. Hayward, J. Perfect, and C. D. Hamilton. “A successful program to optimize use of Amphotericin B Lipid Complex (ABLC) at an academic medical center.” Clinical Infectious Diseases 25, no. 2 (December 1, 1997): 434.
-
Dukes Hamilton, C., R. Drew, S. Hayward, J. Kure, and S. Janning. “Improving clinician adherence to vancomycin-use guidelines: Results of a pharmacist-based strategy at an Academic Medical Center.” Clinical Infectious Diseases 25, no. 2 (December 1, 1997): 425.
-
Gattis, W. A., W. P. Petros, W. W. Pickard, R. H. Drew, D. B. May, and J. W. Hathorn. “A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy.” Pharmacotherapy 17, no. 4 (1997): 836–40.Link to Item
-
Fuller, R. E., R. H. Drew, and J. R. Perfect. “Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin.” Pharmacotherapy 16, no. 4 (1996): 584–92.Link to Item
-
May, D. B., R. H. Drew, K. C. Yedinak, and J. A. Bartlett. “Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers.” Pharmacotherapy 14, no. 5 (1994): 509–13.Link to Item
-
Drew, R. H. “Pharmacotherapy of disseminated histoplasmosis in patients with AIDS.” Ann Pharmacother 27, no. 12 (December 1993): 1510–18. https://doi.org/10.1177/106002809302701218.Full Text Link to Item
-
Drew, R. H., and H. A. Gallis. “Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications.” Pharmacotherapy 12, no. 3 (1992): 161–73.Link to Item
-
Perfect, J. R., M. H. Lindsay, and R. H. Drew. “Adverse drug reactions to systemic antifungals. Prevention and management.” Drug Saf 7, no. 5 (1992): 323–63. https://doi.org/10.2165/00002018-199207050-00003.Full Text Link to Item
-
Gallis, H. A., R. H. Drew, and W. W. Pickard. “Amphotericin B: 30 years of clinical experience.” Rev Infect Dis 12, no. 2 (1990): 308–29. https://doi.org/10.1093/clinids/12.2.308.Full Text Link to Item
-
Gallis, H. A., R. O. Brennan, S. D. Goodwin, V. Swinney, M. M. Rumbaugh, and R. H. Drew. “Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.” Am J Med 87, no. 5A (November 30, 1989): 176S-180S. https://doi.org/10.1016/0002-9343(89)90052-1.Full Text Link to Item
-
Drew, R. H., S. Weller, H. A. Gallis, K. A. Walmer, J. A. Bartlett, and M. R. Blum. “Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus.” Antimicrob Agents Chemother 33, no. 10 (October 1989): 1801–3. https://doi.org/10.1128/AAC.33.10.1801.Full Text Link to Item
-
Drew, R. H., J. R. Perfect, and H. A. Gallis. “Use of fluconazole in a patient with documented malabsorption of ketoconazole.” Clin Pharm 7, no. 8 (August 1988): 622–23.Link to Item
-
Drew, R. H., and H. A. Gallis. “Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.” Pharmacotherapy 8, no. 1 (1988): 35–46. https://doi.org/10.1002/j.1875-9114.1988.tb04063.x.Full Text Link to Item
-
Drew, R. H. “Applying pharmacokinetic principles to the management of drug poisoning.” Pediatr Ann 16, no. 11 (November 1987): 913–24. https://doi.org/10.3928/0090-4481-19871101-10.Full Text Link to Item
-
Drew, R. H., D. I. Templer, B. A. Schuyler, T. G. Newell, and W. G. Cannon. “Neuropsychological deficits in active licensed professional boxers.” J Clin Psychol 42, no. 3 (May 1986): 520–25. https://doi.org/10.1002/1097-4679(198605)42:3<520::aid-jclp2270420319>3.0.co;2-6.Full Text Link to Item
-
Drew, R. H., and C. E. Buckley. “Sulfites in medicines.” N C Med J 45, no. 6 (June 1984): 418–19.Link to Item
-
Drew, R. H. “A new era in pharmacotherapy: the need to understand the principles of therapeutic drug monitoring.” N C Med J 45, no. 4 (April 1984): 213–17.Link to Item
-
Drew, R. H. “The use of hydroxocobalamin in the prophylaxis and treatment of nitroprusside-induced cyanide toxicity.” Vet Hum Toxicol 25, no. 5 (October 1983): 342–45.Link to Item
-
Drew, R. H. “Whatever happened to starch blockers?” N C Med J 44, no. 8 (August 1983): 498.Link to Item
-
-
Book Sections
-
Drew, R. H., and R. W. Moehring. “Practical Antibiotic Stewardship: Implementing an Antibiotic Stewardship Program.” In Practical Implementation of an Antibiotic Stewardship Program, 303–21, 2018. https://doi.org/10.1017/9781316694411.016.Full Text
-
Drew, R. H. “Prevention and treatment of infections in neutropenic cancer patients.” In Koda-Kimble and Young’s Applied Therapeutics: The Clinical Use of Drugs, 1672–89, 2013.
-
Drew, R. H. “Aminoglycosides.” In Infectious Diseases: Third Edition, 2:1373–81, 2010. https://doi.org/10.1016/B978-0-323-04579-7.00137-4.Full Text
-
Drew, R. H., M. D. Johnson, E. D. Ashley, and J. R. Perfect. “Rational use of antifungals for invasive fungal infections in the institutional setting.” In Antibiotic Optimization: Concepts and Strategies in Clinical Practice, 577–644, 2004.
-
-
Conference Papers
-
Gibbs, W. J., R. H. Drew, D. B. May, and E. S. D. Ashley. “Potential impact of the modification of diet in renal disease (MDRD) equation on antibiotic dosing.” In Pharmacotherapy, 25:1456–57. PHARMACOTHERAPY PUBLICATIONS INC, 2005.Link to Item
-
Ashley, E. S. D., B. D. Alexander, J. R. Perfect, and R. H. Drew. “Cost-avoidance associated with infectious diseases clinical research.” In Pharmacotherapy, 23:415–415. PHARMACOTHERAPY PUBLICATIONS INC, 2003.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.